Shanghai Taiyin Biotechnology

Shanghai Taiyin Biotechnology is a Chinese biopharmaceutical company focused on the development of therapeutic monoclonal antibodies and biosimilars. The company's pipeline includes KA, a preclinical biosimilar referencing Xolair (omalizumab) for the treatment of moderate-to-severe asthma, and Mab-TH, a clinical-stage recombinant humanized anti-CD52 monoclonal antibody developed in collaboration with the Lanzhou Institute of Biological Products for indications such as chronic lymphocytic leukemia and multiple sclerosis. Shanghai Taiyin Biotechnology leverages advanced cell culture and perfusion fermentation technologies to optimize antibody production, quality, and biopotency.